RNA vaccine
An RNA vaccine is a vaccine whose active genetic component is RNA encoding an antigen.
An RNA vaccine is a vaccine whose active genetic component is RNA encoding an antigen. After delivery into cells—often using a lipid nanoparticle (LNP)—the RNA directs temporary production of the encoded antigen, allowing the immune system to develop humoral and cellular responses. Depending on the antigen and formulation, these responses may include antigen-specific immunoglobulin G, cytotoxic T cells, and broader T cell mediated immunity. Innate immune pathways, including interferon signaling, NF-κB, STAT6, and inflammatory cytokines such as tumor necrosis factor-α, interleukin-6, interleukin-1β, and interleukin-17A, can also influence the response to vaccination.
RNA vaccines have been investigated for infectious diseases including SARS-CoV-2, respiratory syncytial virus, and chikungunya virus, as well as for therapeutic applications such as pulmonary cancer immunotherapy. The technology includes different RNA chemistries, including unmodified RNA and N1-methylpseudouridine-modified RNA, and can be paired with antigen-engineering strategies designed to broaden immune recognition. Recent work also examines vaccine responses in specific populations, including dialysis patients, and public attitudes toward the use of mRNA vaccination in humans and livestock.
Rebuilt from PubMed 10 Sept 2026 · no new papers today
Where the papers sit
9 papers study rna vaccine directly. Those 9 do not group into themes. Immune responses, reactogenicity, delivery, antigen design and public attitudes all appear, without a shared disease focus or clear direction. They are no more alike than papers drawn from anywhere in the corpus. 1 new direction follows.
Intratracheal mRNA vaccination is presented as a macrophage-reprogramming treatment for established pulmonary cancer
The pulmonary cancer model studied by the intratracheal-delivery paper treats the mRNA vaccine not merely as a vehicle for eliciting systemic antiviral or antitumor immunity, but as a local intervention that selectively reprograms alveolar macrophages. Intratracheal delivery produced only a modest increase in total pulmonary protein expression over intranasal delivery yet greatly increased functional transfection in alveolar macrophages; their depletion abolished antitumor protection. This assigns the RNA vaccine a distinct therapeutic role as a route-dependent immune-cell-targeting treatment for lung tumors 42579432Aug.
Recent Findings on RNA vaccine
Broad mRNA Immunization: Antigen and sequence engineering is broadening mRNA vaccine design, with divergent SARS-CoV-2 RBDs and stabilized RSV pre-fusion F improving breadth or immunogenicity in mice 42647127Aug42172905May. Computational design also predicts a Trypanosoma brucei candidate with broad population coverage and strong receptor binding, but experimental and in-vivo validation remains necessary 42704553Sep. Antigen structure can produce opposing immune outcomes: one CHIKV vaccine induced sustained B-cell activation and IgG-type memory, whereas another produced transient B-cell activation and weaker T-cell responses 42546698Aug. Delivery and innate signaling studies are defining how formulation and administration shape efficacy, as intratracheal lipid nanoparticles target alveolar macrophages, while RNA chemistry and baseline interferon signaling influence humoral responses and reactogenicity 42579432Aug42231579Jun42647597Aug. Clinical and public-health findings remain mixed: BNT162b2 produced higher antibody levels than NVX-CoV2373 in patients on hemodialysis, yet antibody levels declined by week 24 and Australian respondents showed lower acceptance of mRNA vaccination than traditional vaccines 42322683Jun42413319Jul.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-08-31. Last written: 2026-09-09 by GPT. Drafted by language models from published abstracts; not medical advice.